Ciphergen cited a study by researchers at the Johns Hopkins School of Medicine, published in Clinical Chemistry in 2002, that detailed the discovery of three serum biomarkers that can improve the detection of breast cancer.
"Two out of the three markers have since been identified and validated in further studies that were published this month," the company said in a statement. The markers are named C3a and BC1.
Ciphergen said it plans to expand upon these studies in a collaboration with the
Ciphergen did not provide a timeline for the development program.